1
|
Jackson BL, Shafique S, Natale BV, Natale DRC, Winn LM. Investigating the effects of valproic acid on placental epigenetic modifications and development in the CD-1 mouse model. Reprod Toxicol 2024; 124:108551. [PMID: 38280688 DOI: 10.1016/j.reprotox.2024.108551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 01/20/2024] [Accepted: 01/23/2024] [Indexed: 01/29/2024]
Abstract
Gestational exposure to the anticonvulsant drug valproic acid (VPA) is associated with congenital malformations and neurodevelopmental disorders through its action as a histone deacetylase inhibitor. VPA can elicit placental toxicity and affect placental growth and development. The objective of this study was to evaluate the impact of maternal exposure to VPA on the mouse placenta following exposure on gestational day (GD) 13 since previous studies have shown that mice exposed at this time during gestation give birth to offspring with an autism spectrum disorder-like phenotype. We exposed CD-1 dams to a teratogenic dose (600 mg/kg) of VPA or saline on GD13 and assessed fetoplacental growth and development on GD18. We evaluated epigenetic modifications, including acetylated histone H4 (H4ac), methylated H3K4 (H3K4me2) using immunohistochemistry, and global DNA methylation in the placenta at 1, 3, and 24 h following maternal exposure on GD13. In utero exposure to VPA on GD13 significantly decreased placental weight and increased fetal resorptions. Moreover, VPA significantly increased the staining intensity of histone H4 acetylation and H3K4 di-methylation across the placenta at 1 and 3 h post maternal dose. Our results also demonstrate that VPA significantly decreased global DNA methylation levels in placental tissue. These results show that gestational exposure to VPA interferes with placental growth and elicits epigenetic modifications, which may play a vital role in VPA-induced developmental toxicity.
Collapse
Affiliation(s)
- Brianna L Jackson
- Queen's University, Kingston, Ontario K7L 3N6, Canada; Department of Biomedical and Molecular Sciences, Kingston, Ontario K7L 3N6, Canada
| | - Sidra Shafique
- Queen's University, Kingston, Ontario K7L 3N6, Canada; Department of Biomedical and Molecular Sciences, Kingston, Ontario K7L 3N6, Canada
| | - Bryony V Natale
- Queen's University, Kingston, Ontario K7L 3N6, Canada; Department of Biomedical and Molecular Sciences, Kingston, Ontario K7L 3N6, Canada
| | - David R C Natale
- Queen's University, Kingston, Ontario K7L 3N6, Canada; Department of Biomedical and Molecular Sciences, Kingston, Ontario K7L 3N6, Canada
| | - Louise M Winn
- Queen's University, Kingston, Ontario K7L 3N6, Canada; Department of Biomedical and Molecular Sciences, Kingston, Ontario K7L 3N6, Canada; School of Environmental Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.
| |
Collapse
|
2
|
Morel C, Paoli J, Emond C, Debaugnies F, Hardy EM, Creta M, Montagne M, Borde P, Nieuwenhuyse AV, Duca RC, Schroeder H, Grova N. Pharmacokinetic characterisation of a valproate Autism Spectrum Disorder rat model in a context of co-exposure to α-Hexabromocyclododecane. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2024; 105:104343. [PMID: 38122861 DOI: 10.1016/j.etap.2023.104343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 12/06/2023] [Accepted: 12/11/2023] [Indexed: 12/23/2023]
Abstract
Assessing the role of α-hexabromocyclododecane α-HBCDD as a factor of susceptibility for Autism Spectrum disorders by using valproic acid-exposed rat model (VPA) required characterizing VPA pharmacokinetic in the context of α-HBCDD-co-exposure in non-pregnant and pregnant rats. The animals were exposed to α-HBCDD by gavage (100 ng/kg/day) for 12 days. This was followed by a single intraperitoneal dose of VPA (500 mg/kg) or a daily oral dose of VPA (500 mg/kg) for 3 days. Exposure to α-HBCDD did not affect the pharmacokinetics of VPA in pregnant or non-pregnant rats. Surprisingly, VPA administration altered the pharmacokinetics of α-HBCDD. VPA also triggered higher foetal toxicity and lethality with the PO than IP route. α-HBCDD did not aggravate the embryotoxicity observed with VPA, regardless of the route of exposure. Based on this evidence, a single administration of 500 mg/kg IP is the most suitable VPA model to investigate α-HBCDD co-exposure.
Collapse
Affiliation(s)
- C Morel
- Calbinotox EA-7488, Faculty of Science and Technology, University of Lorraine, Campus Aiguillettes, B.P. 70239, 54506 Vandœuvre-lès-Nancy, France.
| | - J Paoli
- Calbinotox EA-7488, Faculty of Science and Technology, University of Lorraine, Campus Aiguillettes, B.P. 70239, 54506 Vandœuvre-lès-Nancy, France; UMR Inserm 1256 nGERE, Nutrition-Génétique et exposition aux risques environnementaux, Institute of Medical Research (Pôle BMS) - University of Lorraine, B.P. 184, 54511 Nancy, France.
| | - C Emond
- Calbinotox EA-7488, Faculty of Science and Technology, University of Lorraine, Campus Aiguillettes, B.P. 70239, 54506 Vandœuvre-lès-Nancy, France; PKSH Inc., Crabtree, Quebec, Canada; School of Public Health, DSEST, University of Montreal, Montreal, Quebec, Canada.
| | - F Debaugnies
- Department of Medical Biology, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg.
| | - E M Hardy
- Department of Health Protection, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg.
| | - M Creta
- Department of Health Protection, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg.
| | - M Montagne
- Department of Health Protection, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg.
| | - P Borde
- Department of Medical Biology, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg.
| | - A Van Nieuwenhuyse
- Department of Health Protection, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg; Environment and Health, Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.
| | - R C Duca
- Department of Health Protection, National Health Laboratory (LNS), Dudelange, Grand Duchy of Luxembourg; Environment and Health, Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.
| | - H Schroeder
- Calbinotox EA-7488, Faculty of Science and Technology, University of Lorraine, Campus Aiguillettes, B.P. 70239, 54506 Vandœuvre-lès-Nancy, France; UMR Inserm 1256 nGERE, Nutrition-Génétique et exposition aux risques environnementaux, Institute of Medical Research (Pôle BMS) - University of Lorraine, B.P. 184, 54511 Nancy, France.
| | - N Grova
- Calbinotox EA-7488, Faculty of Science and Technology, University of Lorraine, Campus Aiguillettes, B.P. 70239, 54506 Vandœuvre-lès-Nancy, France; UMR Inserm 1256 nGERE, Nutrition-Génétique et exposition aux risques environnementaux, Institute of Medical Research (Pôle BMS) - University of Lorraine, B.P. 184, 54511 Nancy, France; Immune Endocrine Epigenetics Research Group, Department of Infection and Immunity-Luxembourg Institute of Health, 29 rue Henri Koch, L-4354, Esch-Sur-Alzette, Grand Duchy of Luxembourg.
| |
Collapse
|
3
|
Ruyani SF, Sumarsono SH. Exposure to Valproic acid (VPA) resulted in alterations in the expression of angiogenic genes (NRP-1, VEGFA, VEGFR-2 and sFlt1) and histological modifications in the placenta of mice (Mus musculus). Reprod Toxicol 2023; 119:108405. [PMID: 37207908 DOI: 10.1016/j.reprotox.2023.108405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 05/15/2023] [Accepted: 05/16/2023] [Indexed: 05/21/2023]
Abstract
Valproic acid (VPA), an anti-epileptic drug (AED), has been reported to exhibit anti-angiogenic properties. This study aimed to examine the impact of VPA on the expression of NRP-1 and additional angiogenic factors, as well as angiogenesis, in mouse placenta. Pregnant mice were divided into four groups: control (K), solvent control (KP), VPA treatment at a dose of 400 mg/kg body weight (BW) (P1), and VPA treatment at a dose of 600 mg/kg BW (P2). The mice were subjected to daily treatment via gavage from embryonic day (E) 9 to E14 and E9 to E16. Histological analysis was performed to evaluate Microvascular Density (MVD) and percentage of the placental labyrinth area. In addition, a comparative analysis of Neuropilin-1 (NRP-1), vascular endothelial growth factor (VEGFA), vascular endothelial growth factor receptor (VEGFR-2), and soluble (sFlt1) expression was conducted in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The results of the MVD analysis and percentage of labyrinth area in the E14 and E16 placentas indicated that the treated groups were significantly lower than the control group. The relative expression levels of NRP-1, VEGFA, and VEGFR-2 in the treated groups were lower than those in the control group at E14 and E16. Meanwhile, the relative expression of sFlt1 in the treated groups at E16 was significantly higher than in the control group. Changes in the relative expression of these genes inhibit angiogenesis regulation in the mouse placenta, as evidenced by reduced MVD and a smaller percentage of the labyrinth area.
Collapse
Affiliation(s)
- Shyfa F Ruyani
- School of Life Sciences and Technology, Institut Teknologi Bandung, 10th Ganesa Street, Bandung, West Java 40132, Indonesia
| | - Sony Heru Sumarsono
- School of Life Sciences and Technology, Institut Teknologi Bandung, 10th Ganesa Street, Bandung, West Java 40132, Indonesia.
| |
Collapse
|